Open-label trial of atomoxetine hydrochloride in adults with ADHD.
Artikel i vetenskaplig tidskrift, 2010

Background: While atomoxetine is an established treatment for attention-deficit/hyperactivity disorder in children, few studies have examined its efficacy for adults. Methods: Open-label trial of atomoxetine in 20 individuals with ADHD, aged 19-47 years, for 10 weeks, and a total of one year for responders. Results: Ten patients met primary efficacy criteria at 10 weeks. Only one patient completed the whole study. Six patients discontinued before 10 weeks and thirteen at 10 weeks or later, mainly because of side-effects (aggression, depressed mood, raised liver enzymes, thyroid hormones, diastolic blood pressure), decreasing efficacy or non-compliance. Conclusion: Fifty percent responded to treatment, but only one patient (5%) felt sufficient improvement to continue for one year. Dosage may have been too low, and baseline impairment too high, for atomoxetine to have sufficient effect on ADHD symptoms in our group of adults. The majority had few side-effects, but several terminated treatment because of adverse effects.

Adult

Adverse effects

Adverse effects

Drug Administration Schedule

Intention to Treat Analysis

Time

Attention Deficit Disorder with Hyperactivity

Propylamines

Administration & dosage

Treatment Outcome

Adrenergic Uptake Inhibitors

Middle Aged

Male

Longitudinal Studies

Administration & dosage

Humans

Patient Selection

Drug therapy

Female

Författare

Mats Johnson

Göteborgs universitet

Mats Cederlund

Göteborgs universitet

Maria Råstam

Göteborgs universitet

Björn Areskoug

Göteborgs universitet

Christopher Gillberg

Göteborgs universitet

Journal of Attention Disorders

1087-0547 (ISSN)

Vol. 13 5 539-545

Ämneskategorier

Psykiatri

DOI

10.1177/1087054709332372

PubMed

19458384